3,423 results match your criteria Systemic Lupus Erythematosus and Pregnancy


No evidence of vertical transmission of SARS-CoV-2 after induction of labour in an immune-suppressed SARS-CoV-2-positive patient.

BMJ Case Rep 2020 Jun 30;13(6). Epub 2020 Jun 30.

Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands

We present a case of a 38+1 weeks pregnant patient (G1P0) with a proven COVID-19 infection, who was planned for induction of labour because of pre-existent hypertension, systemic lupus erythematosus, respiratory problem of coughing and mild dyspnoea without fever during the COVID-19 pandemic in March 2020. To estimate the risk of vertical transmission of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) during labour and delivery, we collected oropharyngeal, vaginal, urinary, placental and neonatal PCRs for SARS-CoV-2 during the period of admission. All PCRs, except for the oropharyngeal, were negative and vertical transmission was not observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2020-235581DOI Listing

Systemic Lupus Erythematosus: Clinical Updates in Women's Health Care Primary and Preventive Care Review.

Authors:
Michelle Petri

Obstet Gynecol 2020 Jul;136(1):226

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease most commonly involving skin, joints, and kidneys. Usually, it presents in women in puberty or early adulthood. This monograph provides an overview of the role of an obstetrician-gynecologist (ob-gyn) in the treatment of SLE patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000003942DOI Listing

Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.

J Thromb Thrombolysis 2020 Jun 25. Epub 2020 Jun 25.

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Capa, Fatih, 34093, Istanbul, Turkey.

The adjusted global antiphospholipid syndrome score (aGAPSS) is a recently developed thrombotic risk assessment score that considers the antiphospholipid antibody (aPL) profile and conventional cardiovascular risk factors. In this retrospective study, we aimed to evaluate the validity of the aGAPSS in predicting clinical manifestations (criteria and extra-criteria) of antiphospholipid syndrome (APS) in a single centre cohort of patients. Ninety-eight patients with APS ± systemic lupus erythematosus (SLE) were classified according to clinical manifestations as vascular thrombosis (VT), pregnancy morbidity (PM) or both (VT + PM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-020-02195-4DOI Listing

VEGF, PlGF and sFlt-1 serum levels allow differentiation between active lupus nephritis during pregnancy and preeclampsia.

Arthritis Care Res (Hoboken) 2020 Jun 25. Epub 2020 Jun 25.

Department of Rheumatology, Universidade do Estado do Rio de Janeiro. Rio de Janeiro, Brazil.

Objectives: To evaluate mean serum levels of VEGF (vascular endothelial growth factor), PlGF (placental growth factor) and sFlt-1 (soluble Fms-like tyrosine kinase-1) in pregnant systemic lupus erythematosus (SLE) patients with inactive disease, active lupus nephritis and preeclampsia for differential diagnosis between these conditions.

Methods: Pregnant women with SLE, with singleton pregnancies and no other autoimmune diseases, were classified according to disease activity (inactive SLE and active lupus nephritis) and presence of preeclampsia. Serum samples were collected within three weeks of delivery and frozen for subsequent blinded analysis through ELISA method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.24360DOI Listing

Competing risks model for prediction of small-for-gestational-age neonates from maternal characteristics and medical history.

Ultrasound Obstet Gynecol 2020 Jun 23. Epub 2020 Jun 23.

Fetal Medicine Research Institute, King's College Hospital, London, UK.

Background: The established method of identifying a group of women at high-risk of delivering SGA neonates, requiring increased surveillance, is use of risk scoring systems based on maternal demographic characteristics and medical history. Although this approach is relatively simple to perform, it does not provide patient-specific risks and has an uncertain performance of predicting SGA. Another approach to predict delivery of SGA neonates is to use logistic regression models that combine maternal factors with first-trimester biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/uog.22129DOI Listing

Exposure to Belimumab in the First Trimester of Pregnancy in a Young Woman With Systemic Lupus Erythematosus.

Reumatol Clin 2020 Jun 19. Epub 2020 Jun 19.

División Clínica Médica, Hospital General de Agudos Juan A. Fernández, Ciudad Autónoma de Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reuma.2020.02.002DOI Listing

Moyamoya syndrome related to systemic lupus erythematosus developing during pregnancy: a case-based review.

Clin Rheumatol 2020 Jun 19. Epub 2020 Jun 19.

Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.

Moyamoya syndrome (MMS) is a chronic cerebrovascular disorder characterized by occlusion or stenosis of the internal carotid arteries with the formation of abnormal collateral vascular networks. Moreover, the development of MMS, which is a distinct category from "moyamoya disease," is attributed to the underlying disease, while some cases of MMS related to systemic lupus erythematosus (SLE) have been previously reported. Herein, we present the case of a 29-year-old Japanese woman with SLE in whom intracranial hemorrhage ascribable to MMS developed during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-020-05246-6DOI Listing

Complement-Mediated Disorders in Pregnancy.

Adv Chronic Kidney Dis 2020 Mar;27(2):155-164

Department of Nephrology/Medicine, Jacobi Medical Center at Albert Einstein College of Medicine, Bronx, NY. Electronic address:

Complement-mediated disorders in pregnancy span a large spectrum and have been implicated in all three complement pathways: classical, lectin, and alternative. Our understanding of these disorders in recent years has advanced due to a better understanding of complement regulatory proteins, such as complement factor H, complement factor I, membrane cofactor protein, and thrombomodulin that particularly affect the alternative complement pathway. Enthusiasm in genotyping for mutations that encode these proteins has allowed us to study the presence of genetic variants which may predispose women to develop conditions such as pregnancy-associated hemolytic uremic syndrome (P-aHUS), thrombotic thrombocytopenic purpura, preeclampsia/hemolysis, elevated liver enzymes, low platelets (HELLP), systemic lupus erythematosus/antiphospholipid syndrome, and peripartum cardiomyopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ackd.2020.01.002DOI Listing

Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review.

Lupus Sci Med 2020 Jun;7(1)

Department of Internal Medicine and Clinical Immunology, CHU and Univerisity of Lille, Lille, France.

Objective: To scope and summarise available literature on the outcomes of pregnancy and associated factors in sub-Saharan African women with SLE.

Methods: Electronic databases and reference lists of retrieved articles were searched to identify relevant studies published from 1 January 2000 to 28 October 2019. Data were combined through narrative synthesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2020-000400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295444PMC

Racial Differences in Contraception Encounters and Dispensing Among Female Medicaid Beneficiaries with Systemic Lupus Erythematosus.

Arthritis Care Res (Hoboken) 2020 Jun 11. Epub 2020 Jun 11.

Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Objective: Black and Hispanic women with SLE have the highest rates of potentially avoidable pregnancy complications, yet racial disparities in family planning among reproductive-age women with SLE have not been well-studied. We examined whether there are racial differences in contraception encounters and dispensing among U.S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.24346DOI Listing

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.

Adv Rheumatol 2020 06 9;60(1):32. Epub 2020 Jun 9.

Pontifícia Universidade Católica de Campinas, Campinas, Brazil.

Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s42358-020-00134-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282202PMC

Rheumatology-led pregnancy clinic: enhancing the care of women with rheumatic diseases during pregnancy.

Clin Rheumatol 2020 Jun 3. Epub 2020 Jun 3.

Rheumatology Department, North Middlesex University Hospital, London, UK.

The autoimmune rheumatic diseases have a clear predilection for women. Consequently, issues regarding family planning and pregnancy are a vital component of the management of these patients. Not only does pregnancy by itself causes physiologic/immunologic changes that impact disease activity but also women living with inflammatory arthritic conditions face the additional challenges of reduced fecundity and worsened pregnancy outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-020-05173-6DOI Listing

Prepregnancy Endocrine, Autoimmune Disorders and the Risks of Gestational Hypertension-Preeclampsia in Primiparas: A Nationwide Population-Based Study in Taiwan.

Int J Environ Res Public Health 2020 May 22;17(10). Epub 2020 May 22.

Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan.

(1) Objective: To assess the risks of gestational hypertension/preeclampsia (GH-PE) in women with prepregnancy endocrine and autoimmune disorders such as polycystic ovarian syndrome (PCOS) and systemic lupus erythematosus (SLE). (2) Methods: In a nationwide population-based longitudinal study, data were retrieved from the 1998 to 2012 Taiwan National Health Insurance Research Database. ICD9-CM codes 256. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph17103657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277106PMC

Perceptions of women with systemic lupus erythematosus undergoing high-risk prenatal care: A qualitative study.

Midwifery 2020 Aug 13;87:102715. Epub 2020 May 13.

Department of Gynecology and Obstetrics, School of Medical Science University of Campinas (UNICAMP), Brazil. R. Alexander Fleming 101, ZIP: 13083-881, Campinas, SP, Brazil. Electronic address:

Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that often leads to situations of harm to the mother-fetus binomial. Given the potential for complications and morbidities in these pregnant women, it is essential that a multidisciplinary team be involved in pregnancy planning, as well as monitoring the course of the pregnancy and the postpartum period. Owing to the imminent risks of disease worsening along with consequent disabilities, these women may experience psychological and psychosocial impacts conflicting with the psychological demands of pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.midw.2020.102715DOI Listing

A preeclampsia risk prediction model for Chinese pregnant patients with systemic lupus erythematosus.

Arthritis Care Res (Hoboken) 2020 May 20. Epub 2020 May 20.

Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

Objective: To screen for a high risk of preeclampsia (PE) in women with systemic lupus erythematosus (SLE).

Methods: Five hundred thirteen antenatal care records of pregnant SLE patients were obtained and the data were randomly assigned to either a development set (n=342) or a validation set (n=171). PE predictors were identified with stepwise regression, and coefficient B of each variable was used to establish a prediction model and risk scoring system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.24265DOI Listing

Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.

J Rheumatol 2020 May 11. Epub 2020 May 11.

From the Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, and the Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. This study was supported by the Rheumatology Research Foundation's Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. The Atherosclerosis Prevention in Pediatric Lupus Erythematosus [APPLE (ClinicalTrials. gov: NCT00065806)] trial is supported by the US National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) contract N01-AR-2-2265, the Edna and Fred L. Mandel Jr. Center for Hypertension and Atherosclerosis, and Pfizer, which provided atorvastatin and matching placebo. S.J.B. receives support from the NIH (5R01-HD076676-04, 1R01HD083003-01, HHSN275201000003I, HHSN275201800003I, HHSN272201500006I 5U24-TR001608-03), the US Food and Drug Administration (5U18FD006298-03), the Patient-Centered Outcomes Research Institute (PCORI), the Rheumatology Research Foundation's Scientist Development Award, the Thrasher Research Fund, and the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation. C.P.H. receives salary support for research from the National Institute for Child Health and Human Development (NICHD; 1K23HD090239; R13HD102136), National Heart Lung and Blood Institute (R61/R33HL147833), FDA (1R01-FD006099, PI: Laughon; and 5U18-FD006298, PI: Benjamin), the US government for his work in pediatric clinical pharmacology (Government Contract HHSN275201800003I, PI: Benjamin under the Best Pharmaceuticals for Children Act), the nonprofit Burrhoughs Wellcome Fund, and other sponsors for drug development in adults and children (dcri.org/about-us/ conflict-of-interest). D.G. receives support for research from the Eunice Kennedy Shriver NICHD (5R01HD096435). A.M. receives research support from the Thrasher Research Fund (www.thrasherresearch.org). L.E.S. receives support for research from the NIH (U19AR069522), PCORI (8177), and the Childhood Arthritis and Rheumatology Research Alliance. She is on the Data Safety Monitoring Board for investigational product trials for UCB (Cimzia) and Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Samples used in this publication were collected as part of NIH/NIAMS (N01-AR-2-2265). A.M.E. receives support from the NIH National Center for Advancing Translational Sciences. G.K.S. receives support for research from the NIH (UG1 HD068258‑06, HHSN272201300017I, 1UL1TR002553-01, R21AI132677) and the Centers for Disease Control and Prevention (200-2012-53663). She chairs an Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). M.C.W. receives support for research from the NIH (1R01-HD076676‑01A1 and 1K24-AI143971), National Institute of Allergy and Infectious Diseases (HHSN272201500006I and HHSN272201300017I), NICHD (HHSN275201000003I), FDA (5U18-FD006298), and the industry for drug development in adults and children. S.J. Balevic, MD, MHS, Department of Rheumatology and Immunology, and Department of Pediatrics, Duke University School of Medicine, and Duke Clinical Research Institute; C.P. Hornik, MD, PhD, Duke Clinical Research Institute, and Department of Pediatrics, Duke University School of Medicine; T.P. Green, MD, MS, Department of Pediatrics, Northwestern University, Feinberg School of Medicine; M.E. Clowse, MD, MPH, Department of Rheumatology and Immunology, Duke University School of Medicine; D. Gonzalez, PharmD, PhD, Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill; A.R. Maharaj, PhD, Duke Clinical Research Institute; L.E. Schanberg, MD, Duke Clinical Research Institute, and Department of Pediatrics, Duke University School of Medicine; A.M. Eudy, PhD, Department of Rheumatology and Immunology, Duke University School of Medicine; G.K. Swamy, MD, Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; B.L. Hughes, MD, MSc, Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; M. Cohen-Wolkowiez, MD, PhD, Duke Clinical Research Institute, and Department of Pediatrics, Duke University School of Medicine. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham, North Carolina 27710, USA. E-mail: Full Release Article. For details see Reprints and Permissions at jrheum. org. Accepted for publication May 14, 2019.

Objective: To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease receiving longterm HCQ compared to target concentrations with reported antiviral activity against the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19).

Methods: We evaluated total HCQ concentrations in serum and plasma from published literature values, frozen serum samples from a pediatric systemic lupus erythematosus trial, and simulated concentrations using a published pharmacokinetic model during pregnancy. For each source, we compared observed or predicted HCQ concentrations to target concentrations with reported antiviral activity against SARS-CoV-2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.200493DOI Listing

Anxiety and depression in reproductive age women with rheumatic diseases.

Rheumatol Int 2020 May 5. Epub 2020 May 5.

Rheumatology Service, Hospital Universitario "Dr. José Eleuterio Gonzalez", Universidad Autónoma de Nuevo León, Av. Gonzalitos 235 Norte, Colonia Mitras Centro, C.P 64460, Monterrey, Nuevo León, Mexico.

Women in reproductive age with rheumatic diseases (RD) are especially vulnerable for depression and anxiety which negatively impacts the pregnancy, birth, and RD. The purpose of this study is to describe the frequency of anxiety and depression symptoms employing the Hospital Anxiety and Depression Scale (HADS) in women in reproductive age. We conducted an observational, single-center, cross-sectional, and descriptive study in reproductive-age, non-pregnant women without a prior psychiatric diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-020-04591-8DOI Listing
May 2020
1.627 Impact Factor

Uncovering molecular targets for regenerative therapy in degenerative disc disease: do small Leucine-Rich proteoglycans hold the key?

Spine J 2020 Apr 25. Epub 2020 Apr 25.

Aravind Medical Research Foundation, Madurai 625020, India.

Background Context: Small leucine-rich proteoglycans (SLRPs) play an essential role in extracellular matrix (ECM) organization and function. Recently, dysregulation of SLRPs has been implicated in degenerative disc disease (DDD). An in-depth analysis using high-throughput proteomic sequencing might provide valuable information on their implications in health and disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.spinee.2020.04.011DOI Listing

Thrombotic thrombocytopenic purpura with Graves' disease during pregnancy.

Proc (Bayl Univ Med Cent) 2020 Apr 23;33(2):270-272. Epub 2020 Jan 23.

Department of Pathology, Baylor University Medical CenterDallasTexas.

Thrombotic thrombocytopenic purpura may be seen with several autoimmune disorders such as immune thrombocytopenia purpura, immune hemolytic anemia, and systemic lupus erythematosus, but it is rarely associated with Graves' disease. We report a patient with thrombotic thrombocytopenic purpura associated with Graves' disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2020.1713029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155955PMC

Maternal and fetal complications associated with systemic lupus erythematosus: An updated meta-analysis of the most recent studies (2017-2019).

Authors:
Wen Rong He Hua Wei

Medicine (Baltimore) 2020 Apr;99(16):e19797

Department of Obstetrics and Gynecology, The First Clinical Medical College of Yangtze University, Jingzhou, Hubei, China.

Background: Recent guidelines provide better treatment and management of pregnancy in women with systemic lupus erythematosus (SLE). In this analysis, we aimed to systematically assess the maternal and fetal complications associated with SLE using the most recent studies (2017-2019) to obtain an updated result of the present situation.

Methods: http://www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019797DOI Listing

[Lupus and thrombophilia : Antiphospholipid syndrome].

Z Rheumatol 2020 May;79(4):332-341

Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.

Even early on thromboembolic events were observed in patients with systemic lupus erythematosus (SLE) until the antiphospholipid syndrome (APS) was described in the 1980s as an independent disorder. The APS is a systemic autoimmune disease often overlapping with SLE in which antiphospholipid autoantibodies, including lupus anticoagulant, can cause a hypercoagulation state, which clinically by definition is manifested as arterial and venous occlusions or pregnancy complications. The pathophysiology has not yet been entirely delineated and the clinical spectrum of associated concomitant manifestations is large. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00786-3DOI Listing

Phenome-Wide Analysis of Short- and Long-Run Disease Incidence Following Recurrent Pregnancy Loss Using Data From a 39-Year Period.

J Am Heart Assoc 2020 Apr 17;9(8):e015069. Epub 2020 Apr 17.

Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences University of Copenhagen Denmark.

Background It is unclear how recurrent pregnancy loss (RPL) impacts disease risk and whether there is a difference in risk between women with or without a live birth before RPL (primary versus secondary RPL). We investigated the disease risk following RPL, and whether there was a difference between primary and secondary RPL. Methods and Results Using population-wide healthcare registries from Denmark, we identified a cohort of 1 370 896 ever-pregnant women aged 12 to 40 years between 1977 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.119.015069DOI Listing
April 2020
2.882 Impact Factor

Lupus-Induced Vasculitis and Multiple Organ Dysfunction Syndrome as the First Presentation of Systemic Lupus Erythematosus (SLE) in Pregnancy.

Am J Case Rep 2020 Apr 14;21:e921299. Epub 2020 Apr 14.

Department of Rheumatology, Henry Ford Hospital/Wayne State University, Detroit, MI, USA.

BACKGROUND Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production leading to inflammation in multiple organs; it commonly affects young women in their child-bearing years. Clinical manifestations are diverse and range from mild arthritis to diffuse alveolar hemorrhage (DAH). DAH is a rare and devastating complication of SLE that carries a mortality rate of up to 50%, despite aggressive therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.921299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176590PMC

A review of fetal and neonatal consequences of maternal systemic lupus erythematosus.

Prenat Diagn 2020 Apr 13. Epub 2020 Apr 13.

Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, NYU Langone Medical Center, New York, New York, USA.

Systemic lupus erythematosus (SLE) primarily affects women of childbearing age and is commonly seen in pregnancy. The physiologic and immunologic changes of pregnancy may alter the course of SLE and impact maternal, fetal, and neonatal health. Multidisciplinary counseling before and during pregnancy from rheumatology, maternal fetal medicine, obstetrics, and pediatric cardiology is critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pd.5709DOI Listing

Inflammatory myositis in systemic lupus erythematosus.

Lupus 2020 Jun 11;29(7):776-781. Epub 2020 Apr 11.

Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, USA.

Background: The coexistence of inflammatory myositis in systemic lupus erythematosus (SLE) has not been extensively studied. In this study, we describe the incidence, distinct types of inflammatory myositis, and risk factors for this finding in a cohort of pediatric and adult SLE patients.

Methods: We identified SLE patients with coexisting myositis followed between 2010 and 2019 at two pediatric hospitals and one adult hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203320918021DOI Listing

Placenta accrete after a frozen-thawed embryo transfer in a systemic lupus erythematosus patient treated with hydroxychloroquine.

Gynecol Endocrinol 2020 Apr 9:1-4. Epub 2020 Apr 9.

Department of Comprehensive Reproductive Medicine, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

Placenta accreta (PA) is a life-threatening disorder associated with decidual maldevelopment and a thin endometrium. Few cases of systemic lupus erythematosus (SLE) pregnancy complicated by PA have been reported, and the background pathophysiology remains elusive. Here, we report a case of PA in SLE pregnancy treated with hydroxychloroquine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09513590.2020.1743652DOI Listing

[Pregnancy with lupus erythematosus-an update].

Z Rheumatol 2020 May;79(4):359-366

Poliklinik für Rheumatologie und Hiller Forschungszentrum, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.

Current research in the field of systemic lupus erythematosus (SLE) and pregnancy focuses on predictors of adverse pregnancy outcomes, the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy and the importance of preconception counselling. In particular, the prospective predictors of pregnancy outcome: biomarkers in antiphospholipid antibody syndrome and SLE (PROMISSE) study adds to the understanding of risk factors for adverse outcomes. There is increasing evidence of the numerous benefits associated with continuing HCQ treatment in pregnancy and for the use of low-dose acetylsalicylic acid in the prevention of preeclampsia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00772-9DOI Listing

Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.

Z Rheumatol 2020 Mar 31. Epub 2020 Mar 31.

Praxiszentrum St. Bonifatius, München, Germany.

Background: Antimalarial medication (AM) plays an important role in the treatment of rheumatic diseases.

Objective: Updated evidence-based recommendations on the safety management of rheumatological treatment with AM are presented.

Methods: A systematic literature search in the databases Medline (PubMed) and Cochrane identified 1160 studies on the safety of treatment with AM in rheumatology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00785-4DOI Listing

Influence of the Period of Abstinence on Semen Quality in a Patient with Systemic Lupus Erythematosus: A Case Report and Review of the Literature.

Case Rep Rheumatol 2020 7;2020:9296858. Epub 2020 Mar 7.

Assisted Reproductive Technology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that can affect fertility. There is currently little information regarding the semen profile of males with SLE. Moreover, there is no consensus on an appropriate period of sexual abstinence for semen analysis and on the use of DNA fragmentation assay, together with multiple semen analyses to document the semen profile in this clinical population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/9296858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085386PMC

The study of factors associated with pregnancy outcomes in patients with systemic lupus erythematosus.

BMC Res Notes 2020 Mar 30;13(1):185. Epub 2020 Mar 30.

Department of Biostatistics and Public Health, Faculty of Health, Kashan University of Medical Sciences, Pezeshk Blvd, 5th of Qotb-e Ravandi Blvd, P.O.Box: 8715973449, Kashan, Iran.

Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease that can lead to unfavorable pregnancy complications in women. This study aimed to evaluate the factors associated with pregnancy outcomes in patients with SLE.

Results: Fifty-nine pregnant women with SLE (121 pregnancies) participated in this retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-020-05039-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108499PMC

Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: A prospective cohort study.

Int J Rheum Dis 2020 May 30;23(5):633-640. Epub 2020 Mar 30.

Direction of Education and Research, Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

Introduction: Several factors have been associated with the development of preeclampsia in women with systemic lupus erythematosus (SLE).

Objective: To identify risk factors associated with preeclampsia in patients with SLE and its impact on fetal outcomes.

Patients And Methods: We studied a prospective cohort of pregnancies in women with SLE from January 2009 to December 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13830DOI Listing

JAK Inhibitors: Prospects in Connective Tissue Diseases.

Clin Rev Allergy Immunol 2020 Mar 28. Epub 2020 Mar 28.

Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No.1 Shuaifuyuan, Beijing, 100730, China.

The dysregulation of the JAK-STAT pathway is associated with various immune disorders. Four JAK inhibitors have been approved for rheumatoid arthritis (RA), and numerous JAK inhibitors are currently being tested in phase II and III trials for the treatment of various autoimmune inflammatory diseases. In this narrative review, we elucidate the involvement of the JAK-STAT signaling pathway in the pathogenesis of connective tissue diseases (CTDs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12016-020-08786-6DOI Listing
March 2020
5.463 Impact Factor

2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.

Ann Rheum Dis 2020 06 27;79(6):713-723. Epub 2020 Mar 27.

Rheumatology and Clinical Immunology Unit, "Attikon" University Hospital, Athens, Greece

Objective: To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN).

Methods: Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement with the formed statements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2020-216924DOI Listing

Update on Lupus Nephritis: Core Curriculum 2020.

Am J Kidney Dis 2020 Mar 24. Epub 2020 Mar 24.

The Ohio State University Wexner Medical Center, Columbus, OH. Electronic address:

Systemic lupus erythematosus is a multisystem autoimmune disease that commonly affects the kidneys. Lupus nephritis (LN) is the most common cause of kidney injury in systemic lupus erythematosus and a major risk factor for morbidity and mortality. The pathophysiology of LN is heterogeneous. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2019.10.017DOI Listing

Maternal risk factors and adverse birth outcomes associated with HELLP syndrome: a population-based study.

BJOG 2020 Mar 19. Epub 2020 Mar 19.

Departments of Paediatrics and of Epidemiology, Biostatistics and Occupational Health, McGill University Faculty of Medicine, Montreal, QC, Canada.

Objectives: We assessed the incidence, risk factors and adverse birth outcomes associated with elevated liver enzymes and low platelets (HELLP) syndrome.

Design: A retrospective population-based cohort study.

Setting: Canada (excluding Quebec), 2012/2013-2015/2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.16225DOI Listing

Low frequency of flares during pregnancy and post-partum in stable lupus patients.

Arthritis Res Ther 2020 03 19;22(1):52. Epub 2020 Mar 19.

Hospital for Special Surgery, 535 E 70th Street, New York, NY, 10021, USA.

Background: Lupus patients are at risk for pregnancy loss, and it has been generally accepted that women with SLE should have low disease activity prior to conception. However, there are conflicting results regarding the effect of pregnancy on SLE flares. This study aims to identify predictors of flares during and after pregnancy in SLE patients with inactive or stable disease activity during the first trimester and to characterize and estimate the frequency of post-partum flares in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-020-2139-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081564PMC

[Antiphospholipid syndrome : Update on diagnostics and management].

Z Rheumatol 2020 Apr;79(3):255-266

Klinik für Rheumatologie und Klinische Immunologie, Charité Universitätsmedizin Berlin, Berlin, Deutschland.

Antiphospholipid syndrome (APS) was first identified in patients with systemic lupus erythematosus (SLE) and frequent occurrence of thromboembolic complications and miscarriages accompanied by detection of anticardiolipin antibodies (aCL). When APS was also later found without an underlying SLE, the so-called primary APS was distinguished from its secondary form with SLE. Even more specific than aCL are the lupus anticoagulant (LA) and antibodies against beta‑2 glycoprotein I (aB2GP I). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00759-6DOI Listing

Pregnancy and autoimmune diseases.

Authors:
Emily C Somers

Best Pract Res Clin Obstet Gynaecol 2020 Apr 14;64:3-10. Epub 2019 Nov 14.

University of Michigan Schools of Medicine & Public Health, Departments of Internal Medicine, Environmental Health Sciences and Obstetrics and Gynecology, 2800 Plymouth Rd, NCRC B14-G236, Ann Arbor, MI 48109-2800, USA. Electronic address:

Autoimmune diseases (AID) are more prevalent in women than in men, and pregnancy-related factors such as hormonal modulation and fetal microchimerism may influence the future risk of maternal AID. For women with AID, optimizing reproductive health requires a continuum of multidisciplinary care that initiates well before the desire for pregnancy is articulated. Family planning is essential so that pregnancy can be timed when disease is stable and to allow for appropriate medication adjustments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpobgyn.2019.11.004DOI Listing

Sexual function and reproduction can be impaired in men with rheumatic diseases: A systematic review.

Semin Arthritis Rheum 2020 06 14;50(3):557-573. Epub 2020 Feb 14.

Department of Rheumatology, Erasmus MC, University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.

Background: Information about the possible effect of rheumatic diseases on male sexual function and reproduction (sexual health) is scarce and difficult to summarize. Factors known to impair sexual health, such as inflammation, medication use and hypogonadism can be present in a significant proportion of male patients with rheumatic diseases.

Objectives: The objective of our study was to systematically review the literature for the influence of paternal rheumatic disease on sexual health, such as sexual function, reproductive hormones, male fertility, pregnancy and offspring outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2020.02.002DOI Listing

[Obstetrics complications of systemic lupus erythematosus and antiphospholipid syndrome: A multidisciplinary management].

Gynecol Obstet Fertil Senol 2020 May 7;48(5):448-452. Epub 2020 Mar 7.

Service de gynécologie-obstétrique, CHU de Bordeaux, place Amélie-abat-Léon, 33076 Bordeaux, France.

The main autoimmune diseases responsible for obstetric complications are systemic lupus erythematosus and antiphospholipid syndrome. They are particularly associated with an increased risk of miscarriage, stillbirth, intrauterine growth restriction, prematurity and pre-eclampsia. Therapeutics to prevent its complications are mainly low dose aspirin and low molecular weight heparins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2020.03.005DOI Listing

Herpes Simplex Virus-2 Hepatitis: A Case Report and Review of the Literature.

Case Rep Med 2020 20;2020:8613840. Epub 2020 Feb 20.

Houston Methodist Hospital, Department of Infectious Diseases, Houston, TX 77030, USA.

Herpes simplex virus (HSV) is a rare cause of hepatitis in pregnancy and the chronically immunosuppressed, with a high propensity to progress to acute liver failure (ALF) and death. Patients typically present with a nonspecific clinical picture that often delays diagnosis and treatment, contributing to the high mortality rate. We present a case of a young female on chronic prednisone and hydroxychloroquine for systemic lupus erythematosus (SLE) who was diagnosed with HSV-2 hepatitis after presenting with right-sided chest and abdominal discomfort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/8613840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054783PMC
February 2020

[2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus].

Authors:

Zhonghua Nei Ke Za Zhi 2020 Mar;59(3):172-185

Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. In 2019, under the leadership of the Chinese Rheumatology Association, a multidisciplinary guideline development group was established. The objective was to develop an evidence-based diagnosis and treatment guideline for SLE in China based on emerging new evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2020.03.002DOI Listing

Cerebral Lupus and Cryptococcal Meningitis in a Pregnant Woman.

J Neurosci Rural Pract 2020 Jan 3;11(1):183-186. Epub 2020 Mar 3.

Neurology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.

Systemic lupus erythematosus (SLE) is a chronic autoimmune and multisystem disorder, which frequently affects young women. During pregnancy, SLE flares could occur up to 65%, with renal and hematological manifestations being the most common. However, reports on neuropsychiatric lupus in pregnant women are scarce. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-3402895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055607PMC
January 2020

Pregnancy and lupus nephritis in developing countries: A systematic review.

Saudi J Kidney Dis Transpl 2020 Jan-Feb;31(1):10-20

Nephrology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Systemic lupus erythematosus (SLE) and lupus nephritis (LN) have a significant impact on the course of pregnancy, as well as on maternal and fetal outcomes. LN in pregnancy can increase the maternal risks of SLE flare, acute kidney injury, preeclampsia, and even death. It also affects fetal outcomes by the increased risk of intrauterine growth retardation, premature delivery, and fetal loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/1319-2442.279928DOI Listing

Adverse pregnancy outcomes and subsequent development of connective tissue disease in the UK: an epidemiological study.

BJOG 2020 07 25;127(8):941-949. Epub 2020 Mar 25.

Faculty of Biological, Medical and Human Sciences, School of Medical Sciences, Maternal and Fetal Health Research Centre, University of Manchester, Manchester, UK.

Objective: This study assessed prevalence of connective tissue disease (CTDs), systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) in women with previous adverse pregnancy outcome compared with uncomplicated livebirths.

Design: Retrospective case-control study.

Setting: UK Primary Care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.16191DOI Listing

Maternal and perinatal outcomes of pregnancies in systemic lupus erythematosus: A nationwide population-based study.

Semin Arthritis Rheum 2020 06 4;50(3):451-457. Epub 2020 Feb 4.

Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, 1650, Section 4, Taiwan Boulevard, Xitun Dist., Taichung 407, Taiwan; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan; Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address:

Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease that develops mainly in women of reproductive age. We aimed to explore the risk of pregnancy complications in Asian patients with SLE.

Methods: From January 2005 to December 2014, we conducted a nationwide case-control study, using Taiwan's National Health Insurance Research Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2020.01.014DOI Listing
June 2020
3.925 Impact Factor

Are pregnancies with lupus but without APS of good prognosis?

Autoimmun Rev 2020 Apr 27;19(4):102489. Epub 2020 Feb 27.

Univ. Lille, EA 2694: Epidémiologie et qualité des soins, F-59000 Lille, France; Univ Lille, CHU Lille, Pôle Femme Mère Nouveau-né, F-59000 Lille, France.

Background: Pregnancies in women with systemic lupus erythematosus (SLE) are at risk of unfavorable perinatal outcomes, especially when antiphospholipid antibody syndrome (APS) is present. Their prognosis is less clear in other situations.

Objectives: To assess pregnancy prognosis in women with SLE but not APS compared with a control series and determine the poor prognostic factors, if any, detectable before 15 weeks' gestation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2020.102489DOI Listing

Preeclampsia Among African American Pregnant Women: An Update on Prevalence, Complications, Etiology, and Biomarkers.

Obstet Gynecol Surv 2020 Feb;75(2):111-120

Professor and Chair, Department of Anesthesiology, State University of New York-Downstate Medical Center, Brooklyn, NY.

Importance: Preeclampsia is a devastating disease of pregnancy associated with increased risk of fetal and maternal complications. African American pregnant women have a high prevalence of preeclampsia, but there is a need of systemic analyses of this high-risk group regarding complications, etiology, and biomarkers.

Objective: The aim of this study was to provide a synopsis of current research of preeclampsia specifically related to African American women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/OGX.0000000000000747DOI Listing
February 2020

[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].

Z Rheumatol 2020 Mar;79(2):186-194

Praxiszentrum St. Bonifatius, München, Deutschland.

Background: Antimalarial medication (AM) plays an important role in the treatment of rheumatic diseases.

Objective: Updated evidence-based recommendations on the safety management of rheumatological treatment with AM are presented.

Methods: A systematic literature search in the databases Medline (PubMed) and Cochrane identified 1160 studies on the safety of treatment with AM in rheumatology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00751-0DOI Listing

2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

Arthritis Rheumatol 2020 04 23;72(4):529-556. Epub 2020 Feb 23.

ECRI Institute, Plymouth Meeting, Pennsylvania.

Objective: To develop an evidence-based guideline on contraception, assisted reproductive technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy (HRT), pregnancy assessment and management, and medication use in patients with rheumatic and musculoskeletal disease (RMD).

Methods: We conducted a systematic review of evidence relating to contraception, ART, fertility preservation, HRT, pregnancy and lactation, and medication use in RMD populations, using Grading of Recommendations Assessment, Development and Evaluation methodology to rate the quality of evidence and a group consensus process to determine final recommendations and grade their strength (conditional or strong). Good practice statements were agreed upon when indirect evidence was sufficiently compelling that a formal vote was unnecessary. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.41191DOI Listing